Splash Beverage expands CannEpil license to veterinary therapeutics; royalty 10% on vet revenue

SPLASH BEVERAGE GROUP, INC.

Expanded exclusive global license for CannEpil to include veterinary applications; royalty 10% of net revenue for vet, 15% for human.
Initial focus on companion-animal oncology and chronic pain management; canine indications expected first.
Global veterinary pain management market ~$2.6B in 2024, projected ~$3.8B by 2030; veterinary oncology market $900M-$1.7B.
Company finalizing strategic joint venture with established cannabinoid pharmaceutical company to lead vet development.
CannEpil is EU-GMP manufactured, has IND for human program; will pursue FDA Center for Veterinary Medicine pathways.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.